BridgeBio Pharma, Inc.BBIONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +237.08% | -44.76% | +4999.86% | +4318.01% | +2521.22% |
| Gross Profit Growth | +231.12% | -45.85% | +6709.68% | +5248.50% | +3553.55% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -30529.15% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +8.58% | +6.40% | +1.56% | +1.06% | +4.12% |
| Weighted Average Shares Diluted Growth | +8.58% | +6.40% | +1.56% | +1.06% | +4.12% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -208.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -218.71% | +0.00% | +0.00% |
| Receivables Growth | +169.67% | -51.05% | +11546.67% | +24276.15% | +2853.07% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +68.26% | +3.80% | +35.98% | +50.12% | +1.82% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -0.53% | +7.49% | +54.81% | +7.51% | +57.68% |
| R&D Expense Growth | +0.10% | -20.96% | -3.02% | -6.29% | +8.94% |
| SG&A Expenses Growth | +99.19% | +61.63% | +116.98% | +99.98% | +92.02% |